Intraday Info: Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) locked on 07/02/2017 at $1.35. It has average volume 410,961 whilst it totals volume 54,024.
Ownership Summary: Dipexium Pharmaceuticals Inc has total institutional ownership 26.61% while its total outstanding shares 10 millions that’s value of holdings $4 million.
Active Positions: In the latest year, DPRX 21 holders have raised its positions while it contains total 300,766 shares. And the strength of reduced positions holders and held positions holders are 18 and 3 respectively.
New and Sold Out Positions: In DPRX force of new positions holders 5 and it has total shares 34,435. And force of sold out positions holders 10 and it has 138,154 shares.
Comparison with Other Company: The Market Value of DPRX is $15,007 below from AbbVie Inc. market value which is $98M. Current Last Sale of DPRX is $1.35 below from ABBV current last sale which is $60.56.
Dipexium pharmaceuticals, Inc. declared that they’ve reached a definitive settlement underneath which PLx Pharma will merge with a completely-owned associate of Dipexium in an all-stock transaction. Following remaining, Dipexium could be renamed PLx Pharma Inc., and will perform beneath the leadership of the PLx administration group with Michael Valentino serving as executive Chairman of the organisation’s Board of administrators and Natasha Giordano serving as President and leader executive Officer.
The combined enterprise will in the beginning be focused on finishing touch of manufacturing scale-up and label finalization for the previously conditionally accepted AspertecTM 325 mg aspirin dosage shape thereby pleasant the open conditional objects, and submitting of a supplemental new drug application (sNDA) for Aspertec eighty one mg maintenance dose form. Aspertec is being evolved to offer excessive-chance cardiovascular and neurology patients with more dependable and predictable antiplatelet efficacy as evaluation to enteric covered aspirin at the same time as additionally lowering the destructive gastric activities common in an acute placing.
Natasha Giordano, President and leader govt Officer of PLx Pharma, said, “This merger will offer PLx Pharma with the initial sources necessary to advance our contemplated improvement efforts for Aspertec and begin the critical pre-commercialization sports vital to prepare the marketplace for this critical cardiovascular product.”